FluSHED-2
Research type
Research Study
Full title
Assessment of viral shedding week following administration of live attenuated influenza vaccine in children: FluSHED-2 study
IRAS ID
250312
Contact name
Paul Turner
Contact email
Sponsor organisation
Imperial College London JRC Office
Eudract number
2018-002470-42
Duration of Study in the UK
0 years, 7 months, 1 days
Research summary
The intranasal 'flu vaccine (LAIV) was introduced into the UK immunisation schedule for children in 2013/14, and Public Health England has since been closely monitoring programme performance. There is a concern about how the vaccine works when given annually over many years, particularly due to data from the USA reporting a drop in effectiveness over recent years following its use in USA for over a decade.
To date, LAIV remains effective in the UK but there is a need to continue monitoring effectiveness. One means of doing this is do assess the "shedding" of the vaccine strains into the nose after vaccination, as this has been shown to relate to vaccine "take".
This is an exploratory study to measure the pattern of "shedding" into the nose that occurs following LAIV vaccination, and how this relates to other biomarkers of successful vaccination. The data will help us optimise strategies to monitor vaccine performance in future studies.
REC name
London - Riverside Research Ethics Committee
REC reference
18/LO/1317
Date of REC Opinion
30 Aug 2018
REC opinion
Further Information Favourable Opinion